Log in

Regeneron Pharmaceuticals Stock Price, Forecast & Analysis (NASDAQ:REGN)

$344.28
+2.49 (+0.73 %)
(As of 11/12/2019 04:20 AM ET)
Today's Range
$338.71
Now: $344.28
$344.99
50-Day Range
$273.46
MA: $300.61
$341.79
52-Week Range
$271.37
Now: $344.28
$442.00
Volume611,923 shs
Average Volume771,700 shs
Market Capitalization$37.81 billion
P/E Ratio17.39
Dividend YieldN/A
Beta1.14
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:REGN
CUSIP75886F10
Phone914-847-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.71 billion
Cash Flow$23.00 per share
Book Value$95.64 per share

Profitability

Net Income$2.44 billion

Miscellaneous

Employees7,400
Market Cap$37.81 billion
Next Earnings Date2/5/2020 (Estimated)
OptionableOptionable

Receive REGN News and Ratings via Email

Sign-up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter.


Regeneron Pharmaceuticals (NASDAQ:REGN) Frequently Asked Questions

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

How will Regeneron Pharmaceuticals' stock buyback program work?

Regeneron Pharmaceuticals declared that its board has approved a share repurchase program on Tuesday, November 5th 2019, which permits the company to buyback $1,000,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to purchase up to 2.9% of its shares through open market purchases. Shares buyback programs are often an indication that the company's management believes its shares are undervalued.

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) issued its quarterly earnings data on Tuesday, November, 5th. The biopharmaceutical company reported $6.67 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $5.13 by $1.54. The biopharmaceutical company earned $2.05 billion during the quarter, compared to analysts' expectations of $1.98 billion. Regeneron Pharmaceuticals had a return on equity of 24.85% and a net margin of 28.13%. Regeneron Pharmaceuticals's revenue was up 23.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $5.87 earnings per share. View Regeneron Pharmaceuticals' Earnings History.

When is Regeneron Pharmaceuticals' next earnings date?

Regeneron Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 5th 2020. View Earnings Estimates for Regeneron Pharmaceuticals.

What price target have analysts set for REGN?

19 analysts have issued twelve-month target prices for Regeneron Pharmaceuticals' stock. Their forecasts range from $320.00 to $453.00. On average, they anticipate Regeneron Pharmaceuticals' share price to reach $387.53 in the next twelve months. This suggests a possible upside of 12.6% from the stock's current price. View Analyst Price Targets for Regeneron Pharmaceuticals.

What is the consensus analysts' recommendation for Regeneron Pharmaceuticals?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 10 hold ratings, 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Regeneron Pharmaceuticals.

What are Wall Street analysts saying about Regeneron Pharmaceuticals stock?

Here are some recent quotes from research analysts about Regeneron Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Regeneron’s third-quarter results were impressive as the company beat on both sales and earnings, driven by the label expansion of blockbuster drug Eylea and strong Dupixent sales in moderate-to-severe atopic dermatitis and asthma. The company’s efforts to expand the label of its approved drugs Eylea and Dupixent, and concurrently develop the pipeline are encouraging. The immuno-oncology platform, which includes Libtayo and a wide portfolio of bispecific antibodies, is progressing well too. However, the company is highly dependent on Eylea for growth and the drug is expected to face competition by the end of the year, which will adversely impact sales. Pipeline setbacks are a concern as well. Shares have underperformed the industry in the year so far." (11/11/2019)
  • 2. Cantor Fitzgerald analysts commented, "We see potential for the pipeline long-term, but from a stock perspective we see more headwinds than tailwinds over the next 12 months for the base business. We think that concerns around competition will continue to be an overhang over 2019 with late-stage readouts in atopic dermatitis. Although we see some potential near-term catalysts with asthma and nasal polyps, we would like to see the hematology and oncology pipeline story emerge a bit more. Valuation Summary We have a 12-month price target of $415 on REGN shares." (2/6/2019)

Has Regeneron Pharmaceuticals been receiving favorable news coverage?

Media coverage about REGN stock has been trending very negative recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Regeneron Pharmaceuticals earned a daily sentiment score of -3.2 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for Regeneron Pharmaceuticals.

Are investors shorting Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals saw a decrease in short interest during the month of October. As of October 31st, there was short interest totalling 2,130,000 shares, a decrease of 6.2% from the September 30th total of 2,270,000 shares. Based on an average trading volume of 691,600 shares, the short-interest ratio is currently 3.1 days. Approximately 2.6% of the shares of the stock are sold short. View Regeneron Pharmaceuticals' Current Options Chain.

Who are some of Regeneron Pharmaceuticals' key competitors?

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include Netflix (NFLX), Celgene (CELG), Gilead Sciences (GILD), Biogen (BIIB), Alibaba Group (BABA), NVIDIA (NVDA), Tesla (TSLA), Amgen (AMGN), Broadcom (AVGO) and Alphabet (GOOG).

Who are Regeneron Pharmaceuticals' key executives?

Regeneron Pharmaceuticals' management team includes the folowing people:
  • Dr. Schleifer Leonard S., Co-Founder, Pres, CEO & Exec. Director (Age 66)
  • Dr. George D. Yancopoulos, Founding Scientist, Pres, Chief Scientific Officer & Director (Age 59)
  • Mr. Robert E. Landry Jr., Exec. VP of Fin. & CFO (Age 55)
  • Mr. Daniel P. Van Plew, Exec. VP and GM of Industrial Operations & Product Supply (Age 46)
  • Ms. Marion E. McCourt, Sr. VP & Head of Commercial (Age 59)

Who are Regeneron Pharmaceuticals' major shareholders?

Regeneron Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (0.43%), Candriam Luxembourg S.C.A. (0.38%), First Trust Advisors LP (0.27%), California Public Employees Retirement System (0.17%), Nikko Asset Management Americas Inc. (0.15%) and Russell Investments Group Ltd. (0.14%). Company insiders that own Regeneron Pharmaceuticals stock include Christopher R Fenimore, George L Sing, Joseph L Goldstein, Michael S Brown, Neil Stahl, P Roy Vagelos and Sanofi. View Institutional Ownership Trends for Regeneron Pharmaceuticals.

Which institutional investors are selling Regeneron Pharmaceuticals stock?

REGN stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., First Trust Advisors LP, Commerzbank Aktiengesellschaft FI, Virginia Retirement Systems ET AL, Bowling Portfolio Management LLC, Great West Life Assurance Co. Can, Mackay Shields LLC and Janney Montgomery Scott LLC. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Christopher R Fenimore, Joseph L Goldstein, Neil Stahl, P Roy Vagelos and Sanofi. View Insider Buying and Selling for Regeneron Pharmaceuticals.

Which institutional investors are buying Regeneron Pharmaceuticals stock?

REGN stock was purchased by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., State of New Jersey Common Pension Fund D, California Public Employees Retirement System, Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Candriam Luxembourg S.C.A., DNB Asset Management AS and Nippon Life Global Investors Americas Inc.. View Insider Buying and Selling for Regeneron Pharmaceuticals.

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Regeneron Pharmaceuticals' stock price today?

One share of REGN stock can currently be purchased for approximately $344.28.

How big of a company is Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals has a market capitalization of $37.81 billion and generates $6.71 billion in revenue each year. The biopharmaceutical company earns $2.44 billion in net income (profit) each year or $19.80 on an earnings per share basis. Regeneron Pharmaceuticals employs 7,400 workers across the globe.View Additional Information About Regeneron Pharmaceuticals.

What is Regeneron Pharmaceuticals' official website?

The official website for Regeneron Pharmaceuticals is http://www.regeneron.com/.

How can I contact Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]


MarketBeat Community Rating for Regeneron Pharmaceuticals (NASDAQ REGN)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  1,276 (Vote Outperform)
Underperform Votes:  1,102 (Vote Underperform)
Total Votes:  2,378
MarketBeat's community ratings are surveys of what our community members think about Regeneron Pharmaceuticals and other stocks. Vote "Outperform" if you believe REGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe REGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/12/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel